Ars Pharmaceuticals Stock Performance
| SPRY Stock | 10.66 0.45 4.41% |
On a scale of 0 to 100, ARS Pharmaceuticals holds a performance score of 6. The firm shows a Beta (market volatility) of 1.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ARS Pharmaceuticals will likely underperform. Please check ARS Pharmaceuticals' kurtosis, market facilitation index, and the relationship between the semi variance and rate of daily change , to make a quick decision on whether ARS Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ARS Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, ARS Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.64 | Five Day Return 0.19 | Year To Date Return (8.79) | Ten Year Return (58.08) | All Time Return (58.08) |
1 | ARS Pharmaceuticals targets renewed growth in 2026 as neffy adoption accelerates and new global launches begin | 11/10/2025 |
2 | Disposition of 21828 shares by Dorsey Brian of ARS Pharmaceuticals, at 0.64 subject to Rule 16b-3 | 11/13/2025 |
3 | ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference | 11/26/2025 |
4 | Why ARS Pharmaceuticals Inc. stock is favored by pension funds - Portfolio Update Report Safe Capital Investment Plans - Newser | 12/04/2025 |
5 | Can ARS Pharmaceuticals Inc. stock hit record highs again - July 2025 Setups Verified Trade Idea Suggestions - Blm Sonu Canavar | 12/19/2025 |
6 | ARS Pharmaceuticals Shares Up 3.4 percent Whats Next | 12/29/2025 |
7 | Assessing ARS Pharmaceuticals Valuation After China Approval Expands Neffy Allergy Market Reach | 01/08/2026 |
8 | ARS Pharma Gains China Approval for Neffy, Roth Reiterates Buy Rating | 01/09/2026 |
9 | ARS Pharmaceuticals Shares Down 12.3 percent Should You Sell | 01/12/2026 |
10 | Critical Comparison Integrated BioPharma versus ARS Pharmaceuticals | 01/20/2026 |
| Begin Period Cash Flow | 71 M | |
| Total Cashflows From Investing Activities | -106.1 M | |
| Free Cash Flow | 13 M |
ARS Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 898.00 in ARS Pharmaceuticals on October 29, 2025 and sell it today you would earn a total of 168.00 from holding ARS Pharmaceuticals or generate 18.71% return on investment over 90 days. ARS Pharmaceuticals is currently generating 0.4377% in daily expected returns and assumes 5.6997% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than ARS, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ARS Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of ARS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 10.66 | 90 days | 10.66 | about 27.22 |
Based on a normal probability distribution, the odds of ARS Pharmaceuticals to move above the current price in 90 days from now is about 27.22 (This ARS Pharmaceuticals probability density function shows the probability of ARS Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.26 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ARS Pharmaceuticals will likely underperform. Additionally ARS Pharmaceuticals has an alpha of 0.0799, implying that it can generate a 0.0799 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). ARS Pharmaceuticals Price Density |
| Price |
Predictive Modules for ARS Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ARS Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ARS Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ARS Pharmaceuticals is not an exception. The market had few large corrections towards the ARS Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ARS Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ARS Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.08 | |
β | Beta against Dow Jones | 1.26 | |
σ | Overall volatility | 1.32 | |
Ir | Information ratio | 0.02 |
ARS Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ARS Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ARS Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ARS Pharmaceuticals had very high historical volatility over the last 90 days | |
| ARS Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Critical Comparison Integrated BioPharma versus ARS Pharmaceuticals |
ARS Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ARS Stock often depends not only on the future outlook of the current and potential ARS Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ARS Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 102.4 M | |
| Cash And Short Term Investments | 314 M |
ARS Pharmaceuticals Fundamentals Growth
ARS Stock prices reflect investors' perceptions of the future prospects and financial health of ARS Pharmaceuticals, and ARS Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ARS Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.56) % | ||||
| Operating Margin | (1.64) % | ||||
| Current Valuation | 818.8 M | ||||
| Shares Outstanding | 98.85 M | ||||
| Price To Book | 6.84 X | ||||
| Price To Sales | 7.26 X | ||||
| Revenue | 89.15 M | ||||
| Gross Profit | 114.87 M | ||||
| EBITDA | (3 M) | ||||
| Net Income | 8 M | ||||
| Total Debt | 42 K | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | 13.55 M | ||||
| Earnings Per Share | (0.81) X | ||||
| Market Capitalization | 1.04 B | ||||
| Total Asset | 351.15 M | ||||
| Retained Earnings | (123.31 M) | ||||
| Working Capital | 310.86 M | ||||
About ARS Pharmaceuticals Performance
Evaluating ARS Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if ARS Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ARS Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 83.29 | 74.03 | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.03 |
Things to note about ARS Pharmaceuticals performance evaluation
Checking the ongoing alerts about ARS Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ARS Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ARS Pharmaceuticals had very high historical volatility over the last 90 days | |
| ARS Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Critical Comparison Integrated BioPharma versus ARS Pharmaceuticals |
- Analyzing ARS Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ARS Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ARS Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ARS Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ARS Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ARS Pharmaceuticals' stock. These opinions can provide insight into ARS Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.